Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 13, 2019 - Issue
Submit an article Journal homepage
75
Views
0
CrossRef citations to date
0
Altmetric
Response to Letter

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Response to letter]

Mitsuhiro Abe1 Department of Respirology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba city, Chiba 260-8670, JapanCorrespondence[email protected]
,
Kenji Tsushima1 Department of Respirology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba city, Chiba 260-8670, Japan;2 Department of Pulmonary Medicine, International University of Health and Welfare, School of Medicine, Narita city, Chiba 286-8686, Japan
&
Koichiro Tatsumi1 Department of Respirology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba city, Chiba 260-8670, Japan
Pages 1687-1688 | Published online: 14 May 2019

References

  • Abe M, Tsushima K, Sakayori M, et al. Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study. Drug Des Devel Ther. 2018;12:3369–3375.
  • Orsatti L, Fortea J, Quaresma M. Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study 45 [Letter]. Drug Des Devel Ther 2019:13: 1177—1178.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.